Scientific article
English

The tyrosine kinase inhibitor nilotinib inhibits SARS‐CoV‐2 in vitro

Published in

Basic & Clinical Pharmacology & Toxicology, vol. 128, no. 4, p. 621-624

Publication date

2021

Abstract

Since the emergence of the severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) at the end of 2019, no vaccine has been approved to counter this infection and the available treatments are mainly directed against the immune pathology caused by the infection. The coronavirus disease 2019 (COVID-19) is currently causing a worldwide pandemic, pointing the urgent need for effective treatment. In such emergency, drug repurposing presents the best option for a rapid antiviral response. We assess here the in vitro activity of nilotinib, imatinib and dasatinib, three Abl tyrosine kinase inhibitors, against SARS-CoV-2. Although the last two compounds do not show antiviral efficacy, we observe inhibition with nilotinib in Vero-E6 cells and Calu-3 cells with EC50s of 1.44 μM and 3.06 μM, respectively. These values are close to the mean peak concentration of nilotinib observed at steady state in serum, making this compound a potential candidate for treatment of COVID-19 in vivo.

Keywords

  • COVID-19
  • SARS-CoV-2
  • Nilotinib
  • Tyrosine kinases inhibitors

Citation (ISO format)

CAGNO, Valeria et al. The tyrosine kinase inhibitor nilotinib inhibits SARS‐CoV‐2 in vitro. In: Basic & Clinical Pharmacology & Toxicology, 2021, vol. 128, n° 4, p. 621–624. doi: 10.1111/bcpt.13537

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

1742-7843
255views
2downloads

Technical informations

Creation

25/08/2021 09:50:00

First validation

25/08/2021 09:50:00

Update

13/10/2025 16:07:24

Status update

16/03/2023 01:11:49

Last indexation

02/11/2026 16:46:48
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated